2026 MaTOS GU | Session V | Novel Diagnostics and Therapies in RCC
Overview
Dr. Chen reviewed CAR T in RCC: improved safety, challenges in solid tumors; new targets and CRISPR-edited therapies show promising durable responses.
Dr. Dizman showed microbiome diversity links to RCC IO outcomes; TOPOSCORE and sMADCAM-1 predict survival; FMT and biotherapeutics show early promise.
Dr. Tang highlighted SBRT in RCC: high local control, low toxicity, delays systemic therapy; promising combo trials with immunotherapy underway.
Dr. Iravani highlighted 89Zr Girentuximab PET/CT in ccRCC: superior accuracy vs CT/MRI; new tracers and CAIX targeting show promise for imaging and therapy.
The panel discussed microbiome, fiber, and CBM588 may predict response; SBRT impacts GFR; biomarkers (VGF, CD70, PSMA, PD-L1) and urine testing aid monitoring.
Dr. Dizman showed microbiome diversity links to RCC IO outcomes; TOPOSCORE and sMADCAM-1 predict survival; FMT and biotherapeutics show early promise.
Dr. Tang highlighted SBRT in RCC: high local control, low toxicity, delays systemic therapy; promising combo trials with immunotherapy underway.
Dr. Iravani highlighted 89Zr Girentuximab PET/CT in ccRCC: superior accuracy vs CT/MRI; new tracers and CAIX targeting show promise for imaging and therapy.
The panel discussed microbiome, fiber, and CBM588 may predict response; SBRT impacts GFR; biomarkers (VGF, CD70, PSMA, PD-L1) and urine testing aid monitoring.
Target Audience
Physicians
This material is non‑CME, no credits are available, and a certificate will not be provided upon completion.
Faculty
Speakers and Panelists:
Yu-Wei Chen, MD, MS
Nazli Dizman, MD
Amir Iravani, MD
Chad Tang, MD
Date of Release
March 20th, 2026
%2016.47.03-1770752981975.webp&w=3840&q=75)
